Try a new search

Format these results:

Searched for:

in-biosketch:true

person:kondzd01

Total Results:

1442


Surgical management options for trigeminal neuralgia [Meeting Abstract]

Lunsford, L. Dade; Niranjan, Ajay; Kondziolka, Douglas
ISI:000254382700001
ISSN: 2005-3711
CID: 193862

Recursive partitioning analysis of prognostic factors for patients with four or more intracranial metastases treated with radiosurgery

Bhatnagar, A K; Kondziolka, D; Lunsford, L Dade; Flickinger, John C
The purpose of this study was to devise a new recursive partitioning analysis (RPA) of patients with four or more intracranial metastases treated with a single radiosurgery procedure to identify a class of patients with extended survival. 205 patients underwent Gamma Knife radiosurgery for four or more intracranial metastases (median = 5, range 4-18) during one session. The median total treatment volume was 6.8 cc (range 0.6-51.0 cc). Radiosurgery was used as sole management (17% of patients), or in combination with WB-RT (46%), or after failure of WB-RT (38%). The median marginal radiosurgery dose was 16 Gy (range 12-20 Gy). RPA assessed the effects of age, Karnofsky >70, extracranial disease, visceral metastases, number of metastases, total treatment volume, history of breast and melanoma primaries on survival. The median overall survival after radiosurgery for all patients was 8 months. RPA identified a favorable subgroup of 78 patients (43% of the series) with a total treatment volume <7 cc and < 7 brain metastases (Class 1), with a median survival of 13 months. This subgroup's survival was significantly better (p <0.00005) than the remaining patients (Class 2) (n=111) with a median survival of 6 months. In conclusion, RPA of multiple brain metastasis patients identified 2 distinct cohorts of patients. Class 1 patients have a total treatment volume <7 cc and < 7 metastases (4-6) with favorable survival after Radiosurgery and Class 2 patients have a total treatment volume > or = 7 cc and/or > or = 7 metastases and have a significantly poorer survival.
PMID: 17535022
ISSN: 1533-0338
CID: 187472

Safety of radiosurgery applied to conditions with abnormal tumor suppressor genes - Comments [Comment]

Pagnini, Paul G.; Kondziolka, Douglas; Gutin, Philip H.; Friedman, William A.
ISI:000246115400016
ISSN: 0148-396x
CID: 193882

Stereotactic radiosurgery: Adjacent tissue injury and response after high-dose single fraction radiation - Part II: Strategies for therapeutic enhancement, brain injury mitigation, and brain injury repair - Comments [Comment]

Kondziolka, Douglas; Cheshier, Samuel; Chang, Steven D.; Gutin, Philip H.; Chen, Joseph C. T.
ISI:000246115400004
ISSN: 0148-396x
CID: 193872

Access to emergency care [Letter]

Watridge, Clarence B; Solomon, Robert A; Grady, M Sean; Popp, A John; Quest, Donald O; Kondziolka, Douglas; Giannotta, Steven L
PMID: 17427593
ISSN: 0002-8045
CID: 187482

Treatment options for third ventricular colloid cysts: Comparison of open microsurgical versus endoscopic resection - Comments [Comment]

Mathiesen, Tiit; Kondziolka, Douglas; Pollock, Bruce E.; Souweidane, Mark M.; Bruce, Jeffrey N.
ISI:000245473100016
ISSN: 0148-396x
CID: 193902

The long-term perspective on meningioma radiosurgery: Experience from over 1,000 tumors [Meeting Abstract]

Kondziolka, Douglas; Mathieu, David; Martin, Juan J.; Madhok, Ricky; Flickinger, John; Niranjan, Ajay; Maitz, Ann; Lunsford, L. Dade
ISI:000245586900052
ISSN: 0022-3085
CID: 193912

Angled screw holes for anterior posts and a frame-positioning device for gamma knife radiosurgery: Allowing for better targeting of intracranial lesions - Comments [Comment]

Pollock, Bruce E.; Kondziolka, Douglas; Regis, Jean; Goodkin, Robert; Noren, Georg
ISI:000245607100038
ISSN: 0148-396x
CID: 193922

Treatment of traumatic brain injury with a combination therapy of marrow stromal cells and atorvastatin in rats - Comments [Comment]

Hawryluk, Gregory; Rutka, James T.; Kondziolka, Douglas; Boulis, Nicholas M.
ISI:000244797000029
ISSN: 0148-396x
CID: 193942

Stereotactic radiosurgery for vestibular schwannomas in patients with neurofibromatosis type 2: an analysis of tumor control, complications, and hearing preservation rates

Mathieu, David; Kondziolka, Douglas; Flickinger, John C; Niranjan, Ajay; Williamson, Richard; Martin, Juan J; Lunsford, L Dade
OBJECTIVE: Vestibular schwannomas present significant management challenges in patients with neurofibromatosis Type 2 (NF2). We evaluated the results of gamma knife radiosurgery for the management of these tumors, focusing on tumor response, hearing preservation, and other factors affecting outcomes. METHODS: Stereotactic radiosurgery was performed to manage 74 schwannomas in 62 patients. Ipsilateral serviceable hearing was present in 35% of tumors before the procedure. The mean tumor volume was 5.7 cm3. The mean margin and maximum dose used were 14 and 27.5 Gy, respectively. Cox regression analyses were performed to identify factors affecting outcomes. RESULTS: The median follow-up period was 53 months, and two patients were lost to follow-up. Actuarial local control rates at were 85, 81, and 81% at 5, 10, and 15 years, respectively. Tumor volume was significant as a predictor of local control. Since 1992, using current radiosurgery techniques (magnetic resonance imaging scan targeting and reduced margin dose to 14 Gy or less), the actuarial serviceable hearing preservation rate is 73% at 1 year, 59% at 2 years, and 48% at 5 years after radiosurgery. Facial neuropathy occurred in 8% of tumors, trigeminal neuropathy occurred in 4%, and vestibular dysfunction occurred in 4%. Radiation dose and tumor volume were predictive of development of new deficits. No radiosurgery-associated secondary tumors or atypical or malignant changes were noted. CONCLUSION: Stereotactic radiosurgery is a safe and effective management modality for neurofibromatosis Type 2 vestibular schwannomas. Although results do not seem to be as good as for patients with sporadic unilateral tumors, gamma knife radiosurgery results seem favorable and indicate that radiosurgery should be strongly considered for primary tumor management in selected patients.
PMID: 17327790
ISSN: 0148-396x
CID: 187512